Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Histiocytosis

Histiocytosis

25

Pipeline Programs↗

21

Active Trials↗

19

Companies Involved↗

Histiocytosis is an emerging landscape with 25 programs across 19 companies. The most active players are Electra Therapeutics Inc.. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

15/100

Mech. Concentration

18/100

Completion Rate

75/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Electra Therapeutics Inc.

1 program

Pipeline

Programs by Phase

Preclinical4

Letermovir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vincristine

Eli Lilly

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Vinblastine Sulfate

Eastern Cooperative Oncology Group

Phase 11

EBV-TCR-T Cells

Fujian Cancer Hospital

Phase 29

Vemurafenib

Conrado Roberto Hoffmann Filho

Clofarabine

Genzyme, a Sanofi Company

Luvometinib

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Tovorafenib

Day One Biopharmaceuticals

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 311

Dose-Modified E-Ru

The First Affiliated Hospital of Soochow University

ELA026

Electra Therapeutics Inc.

Modified-DEP

The First Affiliated Hospital of Soochow University

Vinblastine

Eli Lilly

Methotrexate

Jazz Pharmaceuticals

Approved

No programs

Analysis

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 96% of 25 pipeline programs.

Analysis

Trial Status

48

clinical trials

Recruiting13 · 27%

Completed12 · 25%

Unknown status11 · 23%

Not yet recruiting4 · 8%

Active, not recruiting3 · 6%

Withdrawn2 · 4%

Other3 · 6%

Clinical Trials

Trial Activity

48 trials

Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05828069·48 enrolled

Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis

Recruiting·—·Phase 3·NCT04943211·150 enrolled

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

Recruiting·—·Phase 1·NCT06135922·9 enrolled

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

Recruiting·—·N/A·NCT07488728·80 enrolled

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Recruiting·EElectra Therapeutics Inc.·Phase 2/3·NCT05416307·156 enrolled

Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT06614998·80 enrolled

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Recruiting·—·Phase 2·NCT04943198·25 enrolled

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Recruiting·WWest China Second University Hospital·N/A·NCT07431060·120 enrolled

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

Recruiting·WWest China Second University Hospital·Phase 2·NCT07022834·20 enrolled

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Recruiting·—·Phase 3·NCT02670707·124 enrolled

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Recruiting·CCook Children's Health Care System·Phase 2·NCT06582745·75 enrolled

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting·—·Phase 2·NCT04079179·90 enrolled

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting·NNorth American Consortium for Histiocytosis·Phase 2/3·NCT02205762·1,400 enrolled

A Phase II Study of Lenalidomide for Adult Histiocyte Disorders

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT02523040·12 enrolled

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT02425904·25 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)